vaccinessssssssssssssssssss_1

India begins human trials of its first homegrown coronavirus vaccine

pharmafile | July 21, 2020 | News story | Manufacturing and Production COVID, COVID-19, Vaccine, coronavirus 

India has begun human trials of its first internally developed vaccine for COVID-19.

The Indian Council of Medical Research have allowed both Phase 1 and 2 human trials of Covaxin, the experimental vaccine developed by Bharat Biotech. Lokesh Sharma, the Council’s media coordinator, said: “Trials at some sites began yesterday or before, at some places it will begin today and at some sites it will start tomorrow.”

Bharat Biotech is collaborating with both the Council and the National Institute of Virology, and the trials have begun with 100 of the 375 volunteers in 12 pre-selected hospitals for the Phase I study.  This will assess if the vaccine candidate is safe in humans.

Advertisement

Randeep Guleria, the Director of the All India Institute of Medical Sciences, said: “We are starting the phase-1 of the trial. A second dose will be given after 14 days and then we will collect blood samples after various intervals and we will decide, based on the analysis, what is the effectiveness of this vaccine.”

Bharat Biotech has previously delivered more than 4 billion doses of various vaccines worldwide for diseases like H1N1 and rotavirus.

Conor Kavanagh

Related Content

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Canada awards CSL Seqirus with influenza pandemic vaccine contract

CSL Seqirus has been awarded a contract committing it to manufacturing and delivering influenza vaccines …

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

The Gateway to Local Adoption Series

Latest content